Cellectis S.A. (NASDAQ:CLLS) concluded the trading at $2.50 on Wednesday, November 23 with a rise of 15.21% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $2.17 and 5Y monthly beta was reading 2.12 with its price kept floating in the range of $2.28 and $2.51 on the day. Considering stock’s 52-week price range provides that CLLS hit a high price of $9.57 and saw its price falling to a low level of $2.00 during that period. Over a period of past 1-month, stock came adding 5.49% in its value.
With its current market valuation of $112.60 million. Analysts are in estimates of -$0.45 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$2.22 for 2022 with estimates of that growing to -$2.13 in next year. These estimates are suggesting current year growth of 12.90% for EPS and 4.10% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $13.43 million. They suggested that in the process company could generate revenue of as low as $2.23 million which could climb up to $42.2 million to hit a high. The average estimate is representing an increase of 24.00% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $31.69 million in 2022, which will be -52.80% less from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review CLLS stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 11 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 3 of them are recommending Cellectis S.A. (CLLS) as a Hold, while 5 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 2, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the CLLS stock which is currently positioned at 0. It further provides that stock’s current price level is 6.92% away from its 20-day simple moving average and is 1.95% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 55.99 while volatility remained at 5.41% over the past week which changes to 6.51% when measuring it over the past month. Beta is valued at 2.03, while measure of average true range or ATR is currently at 0.16. In predicting price targets of as low as $2.00 and as high as $36.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $11.80. Stock’s current price level is 20.0% above from estimated low price target while it is -1340.0% below the estimated high; and even if the CLLS’s share succeeded to reach the median price of $10.50, then the outlook of -320.0% could come to the excitement of the investors.
In comparing Cellectis S.A. (CLLS)’s stock with other industry players reveals that stock’s current price change of 15.21% and that of -70.02% over the past 12 months is in competing position with that of Regeneron Pharmaceuticals Inc. (REGN) which saw its stock price fall by -1.85% in the last trading and went through an increase of 13.25% in past 12-month trading. Industry’s another major player uniQure N.V. (QURE) has rise 14.61% up in previous session, but over the past year has faced a fall of -6.26%, while Calithera Biosciences Inc. (CALA) was also down -1.94% however its price remained floating in the red at -88.48% over the same period. Cellectis S.A. has a P/E ratio of 0 against that of Regeneron Pharmaceuticals Inc.’s 15.51. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.
Having a second look at Cellectis S.A. (NASDAQ:CLLS) provides that stock’s average daily trading volume for 3 months was 81.13K, while it jumped to 95250.0 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 45.54 million.
The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 0.67 million which implies a short ratio of 7.02. This shows down a 1.48% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 0.82 million in the previous month. Subtraction of -69.21% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.